TICKERNERD
Menu
CLPTCLPTHealthcare · Medical Devices

CLPT Stock Forecast: Clearpoint Neuro, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$15
+1.12% on the day

The 3 Wall Street analysts covering Clearpoint Neuro, Inc. hold a median 12-month price target of $25 — +62.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 20 of 100 as at 22 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$469.5M
Ticker Nerd rank
20 / 100
Median analyst target
$25
Analysts covering
3
Total return, dividends reinvested
1W
+0.1%
1M
−0.3%
YTD
+12.3%
1Y
+50.0%
From 52W high
−48.1%
From 52W low
+77.4%
$9
$30
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CLPT stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Clearpoint Neuro, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
20 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
62
Size
55
Quality
49
Growth
49
Value
48
Revisions
28
Accruals
24
Volatility
12
Issuance
10

Momentum (62): The shares have been drifting up relative to others.

Issuance (10): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CLPT stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CLPT, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$15$20$25$30Oct 25Jan 26Apr 26Jul 26CLPTHigh $30Median $25Low $22

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says3 analysts
3 Buy0 Hold0 Sell
Low $22Median $25High $30

The green dot is the last close — the median target sits +62.8% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
18 June 2026B. Riley SecuritiesMaintainsBuy$20 → $30
18 Mar 2026B. Riley SecuritiesMaintainsBuy—
5 Mar 2026B. Riley SecuritiesMaintainsBuy—
1 Aug 2025StifelMaintainsBuy—
25 Apr 2025B. Riley SecuritiesMaintainsBuy—
1 Apr 2025StifelMaintainsBuy—
28 Jan 2025B. Riley SecuritiesMaintainsBuy—
21 Jan 2025Lake StreetMaintainsBuy—
27 Aug 2024Lake StreetMaintainsBuy—
13 Mar 2024StifelReiteratesBuy—
24 Oct 2023StifelInitiatesBuy—
9 Aug 2023Lake StreetMaintainsBuy—
16 Feb 2023B. Riley SecuritiesReinstatesBuy$14
5 Apr 2022B. Riley SecuritiesReinstatesBuy$15
18 Mar 2021Lake StreetInitiatesBuy—
17 July 2020B. Riley SecuritiesInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CLPT appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

CLPT analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
3
Fundamentals

Clearpoint Neuro, Inc. (CLPT) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−17.1×

Cheaper than 95% of US stocks

Price / sales
11.1×

Cheaper than 14% of US stocks

Price / book
43.6×

Cheaper than 3% of US stocks

EV / EBITDA
−17.9×

Cheaper than 88% of US stocks

Growth & margins
Revenue growth (YoY)
18.1%

Higher than 67% of US stocks

Earnings growth (YoY)
18.1%

Higher than 57% of US stocks

Gross margin
61.7%

Higher than 75% of US stocks

Operating margin
−94.2%

Higher than 14% of US stocks

Net margin
−81.8%

Higher than 7% of US stocks

Returns & dividend
Return on equity
−226.5%

Higher than 6% of US stocks

Return on assets
−24.4%

Higher than 17% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

CLPT vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
CLPTClearpoint Neuro, Inc.$469.5M
20
SIShoulder Innovations, Inc.$459.3M
18
SGHTSight Sciences, Inc.$446.1M
86
NPCENeuroPace, Inc.$472.3M
90
MASS908 Devices, Inc.$438.2M
84
SENSSenseonics Holdings, Inc.$506.9M
24
PACBPacific Biosciences of California, Inc.$407.7M
43

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Clearpoint Neuro, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CLPT news & analysis

ClearPoint Neuro: Regulatory Momentum Strengthens The Long-Term Investment Case

Seeking Alpha · 4 Aug 2026neutral

ClearPoint Neuro reported weak second-quarter results, particularly in drug delivery disposables, and experienced delays in scaling preclinical services at its new facility, lowering expectations for 2026. However, regulatory clarity has improved, making a revenue inflection likely in 2027/2028 as AMT-130 is commercialized.

Why it matters — The article highlights a mixed outlook for CLPT — near-term operational weakness offset by clearer regulatory prospects that could drive meaningful revenue growth in 2027/2028.

ClearPoint Neuro, Inc. (CLPT) Q2 2026 Earnings Call Transcript

Seeking Alpha · 4 Aug 2026neutral

ClearPoint Neuro, Inc. held its Q2 2026 earnings call, the transcript of which was published by Seeking Alpha.

Why it matters — The earnings call transcript provides investors and analysts with management's discussion of the company's quarterly financial performance and strategic outlook.

ClearPoint Neuro (CLPT) Reports Q2 Earnings: What Key Metrics Have to Say

Zacks Investment Research · 4 Aug 2026neutral

ClearPoint Neuro (CLPT) reported its financial results for the quarter ended June 2026. Zacks notes that beyond headline numbers, it may be useful to compare the company's key metrics to Wall Street estimates and year-ago actuals.

Why it matters — CLPT watchers can check how the company's key operational metrics stacked up against analyst expectations and prior-year results for the quarter.

ClearPoint Neuro, Inc. (CLPT) Reports Q2 Loss, Misses Revenue Estimates

Zacks Investment Research · 3 Aug 2026negative

ClearPoint Neuro reported a quarterly loss of $0.38 per share, wider than the Zacks Consensus Estimate of a $0.29 loss and versus a $0.21 per share loss in the same quarter a year ago. The company also missed revenue estimates.

Why it matters — This indicates ClearPoint Neuro's quarterly financial results came in below analyst expectations on both earnings and revenue.

ClearPoint Neuro Q2 Earnings Call Highlights

MarketBeat · 3 Aug 2026positive

ClearPoint Neuro reported second-quarter 2026 revenue growth and outlined a shift in investment priorities toward clinical capacity, preclinical laboratory services, and technologies intended to support commercial-scale neuro drug delivery.

Why it matters — For CLPT watchers, the revenue growth and the company's stated focus on building clinical and preclinical capacity signal how it is positioning itself to support commercial-scale neuro drug delivery.

FAQ

Frequently asked questions about CLPT stock

What is the CLPT stock price forecast for 2026-2027?

The 3 Wall Street analysts covering Clearpoint Neuro, Inc. have a median 12-month price target of $25, with estimates ranging from $22 to $30. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CLPT stock a buy right now?

Of the 3 analysts covering Clearpoint Neuro, Inc., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Clearpoint Neuro, Inc. 20 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CLPT?

As at 22 Aug 2026, Clearpoint Neuro, Inc. ranks 20 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (62 of 100).

Will CLPT stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts implies +62.8% from the last close, and Ticker Nerd's factor model ranks Clearpoint Neuro, Inc. 20 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CLPT stock forecast for 2030?

No analyst covering Clearpoint Neuro, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CLPT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $22 to $30 over the next 12 months.

How has CLPT stock performed over the past year?

Clearpoint Neuro, Inc. returned +50.0% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Clearpoint Neuro, Inc. do?

ClearPoint Neuro Inc. is a medical device and technology company specializing in minimally invasive neurosurgical and spine procedures.

What is the latest news on CLPT?

The most recent item we track (Seeking Alpha, 4 Aug 2026): "ClearPoint Neuro: Regulatory Momentum Strengthens The Long-Term Investment Case". ClearPoint Neuro reported weak second-quarter results, particularly in drug delivery disposables, and experienced delays in scaling preclinical services at its new facility, lowering expectations for 2026. However, regulatory clarity has improved, making a revenue inflection likely in 2027/2028 as AMT-130 is commercialized.

Company

About Clearpoint Neuro, Inc.

ClearPoint Neuro Inc. is a medical device and technology company specializing in minimally invasive neurosurgical and spine procedures. The firm develops and commercializes MRI-guided platforms that enable precise navigation and controlled delivery of devices and therapies into the brain and spine. Its portfolio centers on the ClearPoint Neuro Navigation System, an integrated solution combining hardware, disposable instruments, and software for procedures such as deep brain stimulation, biopsies, laser ablation, and targeted infusion of cell, gene, and other biologic therapies. ClearPoint Neuro also offers ancillary products including SmartFrame access devices, delivery cannulas, and laser therapy systems, along with clinical and pre-clinical services that support therapy development and procedural execution. Serving healthcare and research centers across North America, Europe, Asia, and South America, the company plays a notable role in the healthcare and life sciences market by enabling high-precision interventions for complex neurological disorders under real-time MRI guidance. Founded in 1998 and headquartered in Solana Beach, California, ClearPoint Neuro operates today as a device, cell, and gene therapy-enabling platform company.

CEO Mr. Joseph Michael Burnett · 160 employees · United States · https://www.clearpointneuro.com